Mesoblast’s Ryoncil is scheduled for a full FDA review in September, but first it will face an advisory committee’s questions. (Getty)
https://www.fiercepharma.com/manufacturing/mesoblast-faces-fda-committee-pushback-over-cell-therapy-manufacturing-clinical-data
